What this study is
The goal of this clinical trial is to learn whether a mindfulness-based intervention can reduce depression and anxiety in autistic adolescents. The main question this trial aims to answer is: Do adolescents who complete MINDful TIME show reductions in depression and anxiety compared to an active control group? Researchers will compare adolescents who complete MINDful TIME to adolescents who are instructed to use a mindfulness meditation mobile-app to see if changes in anxiety and depression differ between the two groups.
Participants will either:
- Attend weekly 90-minute MINDful TIME group meetings through Zoom with their parent or caregiver for a total of 8-weeks and use a mindfulness meditation app daily, or
- Use a mindfulness meditation app daily for 8-weeks
All participants will:
- Attend virtual intake, baseline, and follow-up visits to complete data collection
- Complete a weekly electronic meditation diary
What's being tested
- MINDful TIME
Intervention · BEHAVIORAL
The intervention will include weekly 90-minute group meetings held online through Zoom. Adolescents and parents will meet in separate groups and will learn about mindfulness-based strategies that can be used to manage and reduce stress, anxiety, and depression. They will also learn evidence-based strategies to complete daily guided mindfulness meditations using Happier, a commercially-available mobile app. Participants will be encouraged to meditate using the mobile app for 5-20 minutes each day during and after the 8-week intervention.
- Mindfulness Mobile App
Intervention · BEHAVIORAL
Participants will receive access to the Happier app and brief instruction in Habit Formation strategies at the start of their intervention period. A trained member of the research team will provide participants instructions for anchoring their mindfulness meditation to a pre-existing habit (i.e., their morning bathroom routine). Like the treatment group, participants will be encouraged to meditate using the mobile app for 5-20 minutes each day during and after the 8-week intervention period.
Study details
- Sponsor
- Nicole Matthews, Ph.D.
- Conditions
- Autism Spectrum Disorder
- Enrolling
- 160 people
- Starts
- 2026-03-24
- Est. completion
- 2028-02
- Design
- Open-label, randomized, parallel groups
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 13 Years – 18 YearsSex ALLHealthy volunteers Not acceptedYou may qualify if
- Adolescents must be ages 13 to 18 years
- Formal clinical or educational ASD diagnosis confirmed by the study team (i.e., review of formal diagnostic report from the diagnosing practitioner or Multidisciplinary Evaluation Team report (MET) shared with the research team by the family) )
- Must be willing to be randomized to a treatment or delayed treatment control group
- Must be able to attend at least 7 of the 8 group meetings
- English speaking: Adolescents and their parent/caregivers must be English-speaking because the screening and behavioral measures are in English, as well as the intervention content
You can't join if
- Non-verbal participants will be excluded to ensure test compliance and increase sample homogeneity.
- Participants with IQ scores <70 will be excluded because the intervention was developed for individuals without intellectual disability.
- Participants with a physical disability or co-occurring condition that may prevent participation in the weekly group meetings (e.g., selective mutism; aggressive behavior; inability to participate in a 90-minute video conference meeting each week)
- Participants who report active suicidal ideation
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openSouthwest Autism Research & Resource Center
Phoenix, Arizona, United States
- Nicole Matthews · Contact480-582-9499nmatthews@autismcenter.org
- Nicole L Matthews, Ph.D. · Principal investigator
Recruiting
Study team
Sponsor
Nicole Matthews, Ph.D.
Study ID 00023487
Principal investigator
Nicole Matthews, Ph.D.
Southwest Autism Research & Resource Center
Principal investigator
Blair Braden, Ph.D.
Arizona State University
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.